The analyst estimates that the value of the MDD market in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and Canada) in 2019 was $4.7 billion. By the end of the forecast period in 2029, The analyst projects MDD sales to rise to $9.6 billion in the 8MM, at a modest compound annual growth rate (CAGR) of 7.4%.
Across the 68 markets, sales in the MDD market were $8.8 billion in 2019, growing to $16.2 billion in 2029. The eight major markets represent approximately 53.6% and 59.5% of 68-market sales in 2019 and 2029, respectively.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the major depressive disorder (MDD) market through 2029.
Across the 68 markets, sales in the MDD market were $8.8 billion in 2019, growing to $16.2 billion in 2029. The eight major markets represent approximately 53.6% and 59.5% of 68-market sales in 2019 and 2029, respectively.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the major depressive disorder (MDD) market through 2029.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for major depressive disorder (MDD), covered in the analyst’s report “Major Depressive Disorder: Eight-Market Drug Forecast and Market Analysis - Update”, published in December 2023.
- In addition to patient based forecast sales data for the eight major markets (8MM: US, France, Germany, Italy, Spain, UK,Japan, and Canada), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM MDD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM MDD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1.1 Overview
1.2 68M summary statistics
1.3 Key 8MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy area directors
2.5.3 Epidemiologist
2.5.4 Epidemiology reviewers
2.5.5 Vice President of Disease Intelligence and Epidemiology
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lundbeck
- Mylan
- GSK
- Eli Lilly
- Pfizer
- Merck/MSD
- Janssen
- Otsuka
- AstraZeneca
- Gedeon Richter / Recordati Pharmaceuticals
- Mochida Pharmaceutical
- Meiji Seika Pharma
- Shionogi
- Kyowa Pharmaceutical Industry / Yoshitomi Yakuhin Corp
- AbbVie
- Allergan
- Bausch Health
- Organon
- Bristol-Myers Squibb
- CHEPLAPHARM Arzneimittel
- Sage Therapeutics /Biogen
- Johnson & Johnson
- Relmada Therapeutics
- Intra-Cellular Therapies
- Compass Pathways
- Neumora Therapeutics
- Sirtsei Pharmaceuticals / Arrivo BioVentures
